TLDR
- ARK bought 188,665 CoreWeave shares on October 14, worth $14.7 million in the daily trade report.
- CoreWeave stock fell 15.5% and is down 53% over 12 months on debt concerns.
- ARK sold 31,432 Palantir shares after the stock rose more than 60% since early August.
- ARK also sold Personal Genome Diagnostics, 10X Genomics, Toast and Shopify shares.
- Wall Street rates both CoreWeave and Palantir a Moderate Buy.
Cathie Wood’s ARK Invest bought more CoreWeave shares on Wednesday, October 14, 2026. The firm also sold shares of Personal Genome Diagnostics and Palantir Technologies.
CoreWeave, Inc. Class A Common Stock, CRWV
ARK purchased 188,665 CoreWeave shares, valued at $14,680,023 in the daily trade report. Another report put the value at about $12.4 million.
CoreWeave stock fell 15.5% in regular trading on Wednesday. Shares are down 53% over the past 12 months as concerns about the company’s financial obligations weigh on investors.
CoreWeave’s Debt Concerns
The yield on CoreWeave’s $1.25 billion in unsecured bonds due in 2032 recently touched 15%. Venture capitalist Chamath Palihapitiya warned about possible trouble in AI infrastructure financing. Elon Musk replied with one word: “Yikes.”
The Financial Times reported that CoreWeave is exploring financing from life insurance companies. The company hopes to secure investment-grade financing backed by computing infrastructure.
CoreWeave had debt and lease obligations of about $52 billion as of June.
Hotter-than-expected September inflation data also weighed on markets Wednesday. It raised concerns about more Federal Reserve interest rate hikes.
Wall Street rates CoreWeave a Moderate Buy, with 20 Buy ratings, 5 Holds and 2 Sells over the past three months. The average price target of $143.96 is about 119% above Wednesday’s close.
Palantir and Other ARK Trades
ARK sold 31,432 Palantir shares, valued at $6,558,915 in the trade report. Another report put the figure near $6.3 million. Palantir shares fell 3.7% on Wednesday.
The stock has risen more than 60% since early-August earnings. In that report, second-quarter revenue climbed 93% from a year earlier to $1.94 billion.
Barclays recently started coverage of Palantir at Overweight with a $265 price target. Goldman Sachs upgraded the stock to Buy with a $230 target.
Palantir trades at 163.9 times trailing earnings and 85.5 times expected profits. Its average price target of $210.67 points to a 5% gain.
ARK sold 693,049 shares of Personal Genome Diagnostics for $10,984,826. It also sold 113,555 shares of 10X Genomics for $8,152,113.
The firm sold 337,473 shares of Toast for $10,424,540 and 25,605 shares of Shopify for $4,519,794. It bought 9,577 shares of Meta Platforms for $7,302,462.
ARK bought 44,689 shares of Cerebras Systems for $6,662,683 and 110,037 shares of Freenome for $1,390,867. It also added 500,457 shares of Kodiak AI.
ARK bought 459 shares of Scribe Therapeutics for $8,776. CoreWeave shares slipped another 3.5% after hours on Wednesday.
